Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVX-2 for HPV16+ Cervical Dysplasia
NCT03911076Phase 2Terminated
- Sponsor
- PapiVax Biotech, Inc.
- Start
- May 2019
- Primary completion
- Jun 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of Alb-Flt3L fusion protein in human papillomavirus type 16 infection, cervical intraepithelial neoplasia (CIN), sponsored by PapiVax Biotech, Inc.. Started May 2019; status: terminated.
02
Drugs
Alb-Flt3L fusion protein
03
Conditions
human papillomavirus type 16 infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT03911076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911076.